Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several claims about carvedilol indications and common β-blocker class effects are generally consistent with the provided label excerpts, but multiple claims about Coreg CR (extended-release meaning, formulation, dosing frequency, and “should not be crushed or split”) are not supported by the provided prescribing information. The label text provided also does not describe Coreg CR dosing frequency or crushing/splitting instructions.
Category Scores
Accurate Statements
Carvedilol is a beta-blocker.
11 DESCRIPTION: “Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity.”
Carvedilol is used to treat heart failure.
1.1 Heart Failure: “COREG is indicated for the treatment of mild-to-severe chronic heart failure…”
Carvedilol is used to treat hypertension (high blood pressure).
1.3 Hypertension: “COREG is indicated for the management of essential hypertension.”
Dizziness or lightheadedness can occur with carvedilol, especially when starting or changing dose.
5.3 Hypotension: postural hypotension/syncope and risk highest during first 30 days/up-titration; patient counseling: “drop in blood pressure… resulting in dizziness.”
Low blood pressure can occur with carvedilol.
5.3 Hypotension: “hypotension and postural hypotension occurred…”; patient counseling on drop in blood pressure when standing.
Slow heart rate can occur with carvedilol.
5.2 Bradycardia: “COREG caused bradycardia…” and dose reduction if pulse rate drops below 55 bpm.
Fatigue can occur with carvedilol.
17 Patient Counseling Information includes “If experiencing dizziness or fatigue…”
Beta-blockers can worsen bronchospasm in some people with asthma or other breathing disorders.
5.5 Non-allergic Bronchospasm: “Patients with bronchospastic disease… should, in general, not receive β-blockers.”
Carvedilol can interact with drugs that affect heart rate and blood pressure.
7.2 Hypotensive Agents: observation for “signs of hypotension and/or severe bradycardia”; clonidine with β-blocker may cause hypotension and bradycardia.
Unsupported Statements
Coreg CR 10 mg is a brand formulation of carvedilol extended-release.
The provided label excerpts describe COREG (immediate-release film-coated tablets) and do not include Coreg CR description or confirm “CR” as extended-release.
In Coreg CR, "CR" means the tablet is extended-release.
No provided label text defines “CR” as extended-release for Coreg CR.
The "10 mg" on Coreg CR refers to the amount of carvedilol in each extended-release tablet.
The provided label excerpts list COREG strengths (3.125, 6.25, 12.5, 25 mg) but do not provide Coreg CR 10 mg information or explain the “10 mg” meaning for Coreg CR.
Extended-release products are designed to provide steadier blood levels throughout the dosing interval compared with immediate-release carvedilol.
No extended-release pharmacology/AE claims or comparison with immediate-release are included in the provided label text.
Coreg CR is an oral extended-release medication.
No provided label excerpts for Coreg CR establish extended-release characteristics.
Coreg CR is usually taken once daily.
No provided label excerpt states Coreg CR dosing frequency.
Extended-release carvedilol should not be crushed or split.
No provided label text includes instructions about crushing/splitting Coreg CR tablets.
Swelling can occur with carvedilol, sometimes seen with heart failure treatment changes.
Provided warnings include “Heart Failure/Fluid Retention” (worsening heart failure or fluid retention) but do not explicitly state “swelling” as an adverse reaction.
Coreg CR is extended-release carvedilol.
No provided label excerpts confirm that Coreg CR is extended-release.
Coreg is typically immediate-release carvedilol.
The provided label text discusses COREG tablet properties but does not explicitly state it is “typically immediate-release.”
Switching between carvedilol formulations usually requires clinician guidance because dosing and timing can differ.
No provided label text discusses switching between carvedilol formulations or differences in dosing/timing.
Contradictions
Low
AI Statement
Extended-release carvedilol should not be crushed or split.
Label Reference
Absent in provided label excerpts (no statement about crushing/splitting).
Low
AI Statement
Coreg CR is usually taken once daily.
Label Reference
Absent in provided label excerpts (no Coreg CR dosing frequency).
Important Omissions
For Coreg/Carvedilol: specific dosing instructions (dose titration schedule, starting dose, and maximum dose) are not provided in the supplied excerpts, limiting evaluation of any dosing claims.
Importance:
Moderate
Contraindications and boxed warnings were not evaluated because the supplied excerpts do not include the relevant sections (e.g., Contraindications (4) and Boxed Warnings if present).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Coreg CR-specific formulation/dosing/following instructions (extended-release meaning, once-daily frequency, and crushing/splitting) were not supported by the provided label excerpts. If incorrect, these gaps could affect safe administration.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple Coreg CR / extended-release / dosing-frequency / tablet-modification claims are not supported by the provided prescribing information excerpts.
Suggested Improvement
Restrict claims to what is present in the provided label text (COREG indications; hypotension/bradycardia/bronchospasm precautions; interactions described in 7.2). Remove or re-verify Coreg CR-specific statements (e.g., “CR means extended-release,” once-daily dosing, and do-not-crush/split guidance) using the Coreg CR prescribing information sections not included in the prompt.